Faculty Position: Early Cancer Detection and Interception Physician and Scientist Investigators

Mayo Clinic • Phoenix, AZ

3d • Hybrid

About The Position

The Mayo Clinic and Mayo Clinic Comprehensive Cancer Center (MCCCC) are seeking open-rank faculty positions for Early Cancer Detection and Interception roles. These positions require strong leadership potential and a commitment to advancing cancer research into clinical impact. Mayo Clinic and MCCCC have established a significant research hub focused on transforming cancer patient care through actionable target discovery and next-generation discovery and therapeutic platforms. This includes the Mayo Clinic Platform, which holds extensive digitized patient records, and robust AI-driven discovery, translational, and clinical programs. The Cancer Risk Assessment, Early Detection, and Interception (REDI) Research Program is a key initiative. These roles will lead transformative efforts from discovery to clinical science in cancer early detection, prevention, and data-driven translation. The focus is on integrating discovery and translational science, clinical care, genomics, advanced analytics, and community engagement to redefine cancer detection, monitoring, and prevention, with a particular emphasis on cancer interception – delaying or preventing cancer development or progression in pre-cancer and high-risk populations.

Requirements

• Strong leadership potential
• Commitment to advancing cancer research into clinical impact

Nice To Haves

• Faculty positions in Early Cancer Detection and Interception

Responsibilities

• Design and lead prospective cohorts of healthy individuals and high-risk populations to study cancer initiation, progression, and interception.
• Develop strategies to identify individuals at risk (pre-cancer) and guide them to appropriate screening, prevention, and early intervention pathways.
• Integrate clinical, genomic, and longitudinal health data to monitor disease evolution and enable early therapeutic intervention and clinical trials.
• Partner with institutional programs to implement comprehensive, clinical-grade genomic sequencing initiatives or other AI-based multimodal predictive algorithms for early cancer detection and guiding interception in community-based screening and clinical settings.
• Expand cancer risk evaluation to include AI-driven, multi-parametric models incorporating multiple variables (e.g., longitudinal clinical data, radiomics, digital pathology, genetics/genomics, exposome, epidemiology and behavioral data, etc.).
• Expand access to advanced genomic diagnostics across diverse care settings and utilize genomic insights to inform risk assessment, early detection, and personalized treatment strategies.
• Collaborate with discovery science investigators to develop, test and validate novel methods for early cancer detection and diagnosis.
• Lead and develop a translational science program focused on early detection, cancer interception (including immunoprevention).
• Utilize data warehouses unifying clinical, genomic, imaging, and outcomes data.
• Lead the development of data surveillance and visualization tools to monitor cancer trends across patient populations and communities.
• Partner with clinical and community organizations to build collaborative, community-based clinical trial networks, focused on prevention and early detection/screening trials.
• Expand access to innovative trials and precision medicine approaches in diverse and underserved populations.
• Extend institutional impact nationally and globally through scalable models of care and research.
• Build and lead large-scale, longitudinal patient cohorts.
• Drive discovery science and/or develop clinical-grade genomic programs.
• Leverage integrated data platforms, artificial intelligence, and digital health tools to improve patient outcomes and expand access to cutting-edge care.
• Shape a coordinated, forward-looking therapy strategy that advances precision medicine for cancer risk determination and clinical translation of therapeutics directed at preventing cancer development or progression of nascent disease.

Benefits

• Competitive startup and sustained institutional support
• Investment in team science and program-building initiatives
• Access to a $1B+ annual research enterprise
• Infrastructure for IND-enabling studies and early-phase clinical trials
• Exceptional benefits, including retirement and pension programs
• A culture that values innovation, inclusion, and transdisciplinary collaboration

What This Job Offers

• Job Type: Full-time
• Career Level: Senior
• Education Level: Ph.D. or professional degree